RecallRadar

FDA Drug recall D-1177-2023

Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, M…

On 2023-10-04 the FDA classified a Class II recall of Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, M… by Sofie, citing lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1177-2023
ClassificationClass II
Statusterminated
Initiated2023-08-22
Published2023-10-04
Last updated2026-09-13 11:52 UTC
CompanySofie
DistributionVA

Product

Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50

Reason

Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).

Identifiers

ndc54828-001-30
ndc54828-001-50
code_infoBatch # FBBVA123082201, EOS: 22 Aug 2023/08:25, EXP: 22 Aug 2023/18:25

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1177-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.